Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Mylan teams up with Revance on biosimilar for Botox

Mylan NV struck a licensing agreement with Revance Therapeutics Inc. to develop a biosimilar of Allergan Plc’s blockbuster Botox wrinkle treatment.

Read More »

Covance, GSK Ink Strategic Technology Agreement

LabCorp, a leading global life sciences company, announced that its Covance Drug Development business entered into a strategic technology agreement with GlaxoSmithKline plc (GSK).

Read More »

Doctor admits disclosing patient info to Aegerion

A Georgia pediatric cardiologist pleaded guilty to wrongfully disclosing info about his patients to an Aegerion sales rep seeking to identify potential new users of an expensive cholesterol drug.

Read More »

FDA approves Sorrento’s non-opioid painkiller patch

The U.S. Food and Drug Administration approved ZTlido, Sorrento Therapeutics Inc.’s non-opioid painkiller patch for nerve pain related to shingles.

Read More »

Coca-cola defeats U.S. lawsuit over Diet Coke ads

A federal judge dismissed a lawsuit claiming that Coca-Cola Co.’s advertising for Diet Coke misleads people into thinking that consuming the soft drink assists in weight loss, and that it actually causes weight gain.

Read More »

Viela Bio Spins Out of AstraZeneca’s MedImmune with $250 Million Series A Funding

Viela Bio, based in Gaithersburg, Md., spun out of AstraZeneca Pharmaceuticals’ MedImmune with a Series A financing of up to $250 million.

Read More »

Inscripta Snags $55.5 Million in Funding

Gene-editing company Inscripta will be able to expand its research capabilities and increase hiring after the company closed a Series C funding round of $55.5 million.

Read More »

European regulators to help early Alzheimer’s drugs

The European Medicines Agency is following in the footsteps of the U.S. Food and Drug Administration with plans to help pharma companies win approval for novel Alzheimer’s drugs.

Read More »

Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis

Valeant Pharmaceuticals International Inc. announced that its subsidiary entered into an exclusive license agreement with Kaken Pharmaceutical Co. Ltd. to develop and commercialize products containing a new chemical entity, KP-470, which is an investigational compound for the topical treatment of psoriasis.

Read More »

U.S. FDA rejects filing for Celgene MS drug, shares fall

U.S. health regulators rejected Celgene Corp.’s application seeking approval of a key multiple sclerosis drug due to insufficient data, the company said.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom